Equity Field Notes from temporal sources

[DanWebzster]

ZYNE (update)

There are 19 FDA orphan Drug Designations for Fragile X Syndrome. If this treatment makes it all the way to FDA approval, It better have the advantage of market exclusivity.

In Medical Cannabis states, Fragile X patients would do well to try products that take advantage of the Entourage Effect. Rx Green and Mary's Medicinals produce transdermal patches. I doubt ZYNE's patch would prevail in a double blind trial against these products.

I'm watching ZYNE's capital levels closely. It will probably dilute in 2018.